The LGG patients received longer survival times when they expressed lower levels of TRAF6 and IRAK1 but GBM patients did not obtain a remarkable benefit (Fig. 4H and Supplementary Fig. S2B), which might be caused by a large number of infiltrating M2-like GAMs rather than M1-like GAMs. The gene discussed is TRAF6; the disease is glioblastoma.